Hormone receptor expression is associated with a unique pattern of metastatic spread and increased survival among HER2-overexpressing breast cancer patients

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 32, Issue 5, 2009, Pages 504-508

  Paluch Shimon, Shani ^a   Ben Baruch, Noa ^b   Wolf, Ido ^a,c   Zach, Lior ^a,c   Kopolovic, Juri ^a,c   Kruglikova, Anna ^b   Modiano, Tami ^a   Yosepovich, Ady ^a,c   Catane, Raphael ^a,c   Kaufman, Bella ^a,c  

^a SHEBA MEDICAL CENTER   (Israel)

^b KAPLAN MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Breast cancer; HER2; Hormone receptors; Metastases

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR; TRASTUZUMAB;

ADULT; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; LIVER METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; OVERALL SURVIVAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; VISCERAL METASTASIS;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION; HUMANS; NEOPLASM METASTASIS; PROGNOSIS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 70350628847     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3181967d72     Document Type: Article

References (35)

1. Yarden Y, Sliwkowski M. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2:127-137.
2. Burstein J. The distinctive nature of HER2-positive breast cancers. N Engl J Med. 2005;353:1652-1654.
3. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177-182.
4. Aruga R, Zarif A, Korasick J, et al. Correlation of Her2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma. Breast J. 2005;11:278-280.
5. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of Chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over expresses HER2. N Engl J Med. 2001;344:783-792.
6. Piccart M, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353: 1659-1672. (Pubitemid 41464705)
7. Romond E, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemother- apy for operable HER2-positive breast cancer. N Engl J Med. 2005;353: 1973-1984.
8. Kirsch DG, Loeffler JS. Brain metastases in patients with breast cancer: new horizons. Clin Breast Cancer. 2005;6:115-124.
9. Bendell JC, Domchek SM, Burstein HJ, et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer. 2003;97:2972-2977.
10. Clayton AJ, Danson S, Jolly S, et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer. 2004;91:639-643.
11. Lai R, Dang CT, Malkin MG, et al. The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma. Cancer. 2004;101:810-816.
12. Shmueli E, Wigler N, Inbar M. Central nervous system progression among patients with metastatic breast cancer responding to trastuzumab treatment. Eur J Cancer. 2004;40:379-382.
13. Li YM, Pan Y, Wei Y, et al. Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell. 2004;6:459-469.
14. Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410:50-56.
15. Alanko A, Heinonen E, Scheinin T, et al. Significance of estrogen and progesterone receptors, disease-free interval, and site of first metastasis on survival of breast cancer patients. Cancer. 1985;56:1696-1700.
16. de la Monte SM, Hutchins GM, Moore GW. Estrogen and progesterone receptors in prediction of metastatic behavior of breast carcinoma. Am J Med. 1984;76:11-17.
17. Pichon MF, Broet P, Magdelenat H, et al. Prognostic value of steroid receptors after long-term follow-up of 2257 operable breast cancers. Br J Cancer. 1996;73:1545-1551.
18. Osborne CK, Shou J, Massarweh S, et al. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res. 2005;11:865-870.
19. Lipton A, Ali SM, Leitzel K, et al. Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol. 2002;20:1467-1472.
20. Shou J, Massarweh S, Osborne CK, et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-her2/neu cross-talk in er/her2-positive breast cancer. J Natl Cancer Inst. 2004;96:926-935.
21. Schiff R, Massarweh S, Shou J, et al. Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clin Cancer Res. 2003;9:447s- 454s. (Pubitemid 36105786)
22. Harrari D, Yarden Y. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene. 2000;19:6102-6114.
23. Yang Z, Barnes CJ, Kumar R. Human epidermal growth factor receptor 2 status modulates subcellular localization of and interaction with estrogen receptor α in breast cancer cells. Clin Cancer Res. 2004;10:3621-3628.
24. Perissi V, Menini N, Cottone E, et al. AP-2 transcription factors in the regulation of the ERBB2 gene transcription by oestrogen. Oncogene. 2000; 19:280-288.
25. Newman S, Bates NP, Vernimmen D, et al. Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer to oestrogen repression of ERBB2 expression in breast cancer. Oncogene. 2000;19:490-497.
26. Breast cancer. In: Fleming ID, Cooper JS, Henson DE, eds. American Joint Committee on Cancer Staging Manual. 5th ed. Philadelphia, PA: Lippincott- Raven; 1997.
27. Brufsky A, Lembersky B, Schiffman K, et al. Hormone receptor status does not affect the clinical benefit of trastuzumab therapy for patients with metastatic breast cancer. Clin Breast Cancer. 2005;6:247-1245
28. Slimane K, Andre F, Delalogue S, et al. Risk factors for brain relapse in patients with metastatic breast cancer. Ann Oncol. 2004;15:1640-1644.
29. Gonzalez-Angulo AM, Cristofanilli M, Strom EA, et al. Central nervous system metastases in patients with high-risk breast carcinoma after multimodality treatment. Cancer. 2004;101:1760-1766.
30. Evans AJ, James JJ, Cornford EJ, et al. Brain metastases from breast cancer: identification of a high-risk group. Clin Oncol (R Coll Radiol). 2004;16:345-349.
31. Pestalozzi BC, Zahrieh D, Price KN, et al. Identifying breast cancer patients at risk of central nervous system metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol. 2006;17:935-944.
32. Hall JM, Korach KS. Stromal cell-derived factor 1, a novel target of estrogen receptor action, mediates the mitogenic effects of estradiol in ovarian and breast cancer cells. Mol Endocrinol. 2003;17:792-803.
33. Jin C, Fu WX, Xie LP, et al. SDF-1alpha production is negatively regulated by mouse estrogen enhanced transcript in a mouse thymus epithelial cell line. Cell Immunol. 2003;223:26-34.
34. Kim R, Arihiro K, Emi M, et al. Potential role of HER-2; in primary breast tumor with bone metastasis. Oncol Rep. 2006;15:1477-1484.
35. Cui X, Schiff R, Arpino G, et al. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol. 2005;23:7721-7735.